Psychosocial impact and effectiveness of tadalafil among treatment-naïve and previously-treated men with erectile dysfunction in Saudi Arabia and other Gulf-region countries

Current Medical Research and Opinion

Volumn 24, Issue 7, 2008, Pages 1965-1973

  El Khiat, Yasser ^a   Ghazi, Sherif ^a   Allam, Ahmed ^b   Khawaja, Maqsood ^c   Belger, Mark ^d   Tamer, Mohammed ^d   Kopernicky, Vladimir ^e,f  

^a CAIRO UNIVERSITY   (Egypt)

^b Elaj Medical Group   (Saudi Arabia)

^c Riyadh Care Hospital   (Saudi Arabia)

^d ELI LILLY AND COMPANY   (United States)

^e Eli Lilly Area Medical Center   (Austria)

^f Lilly Area Medical Center Vienna   (Austria)

Author keywords

Effectiveness; Erectile dysfunction; Psychosocial impact; Tadalafil

Indexed keywords

SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; ERECTILE DYSFUNCTION; ERECTILE FUNCTION DOMAIN SCORE; GLOBAL ASSESSMENT QUESTION; HEART RATE; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; KUWAIT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; PENIS ERECTION; PSYCHOLOGICAL AND INTERPERSONAL RELATIONSHIP SCALE; QUESTIONNAIRE; SAUDI ARABIA; SCORING SYSTEM; SELF ESTEEM; SEXUAL BEHAVIOR; SIDE EFFECT; SOCIAL PSYCHOLOGY; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNITED ARAB EMIRATES; VASCULAR DISEASE;

ADULT; CARBOLINES; ERECTILE DYSFUNCTION; HUMANS; KUWAIT; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; SAUDI ARABIA; SEXUALITY; TREATMENT OUTCOME; UNITED ARAB EMIRATES;

EID: 47949087164     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802190641     Document Type: Article

References (11)

1. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
2. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-6
3. El-sakka AI. Characteristics of erectile dysfunction in Saudi patients. Int J Impot Res 2004;16:13-20
4. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, et al. Diabetes mellitus in Saudi Arabia. Saudi Med J 2004;25:1603-10
5. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes. Diabetes Care 2004;27:1047-53
6. Martin-Morales A, Haro JM, Beardsworth A, et al. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the Erectile Dysfunction Observational Study (EDOS). Eur Urol 2007;51:541-50
7. Swindle R, Cameron A, Rosen R. A 15-item short form of the psychological and interpersonal relationship scales. Int J Impot Res 2006;18:82-8
8. Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for the assessment of erectile dysfunction. Urology 1997;49:822-30
9. Dean J, Hackett GI, Gentile V, et al. Psychosocial Outcomes and Drug Attributes Affecting Treatment Choice in Men Receiving Sildenafil Citrate and Tadalafil for the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Open-Label, Crossover Study. J Sex Med 2006;3:650-61
10. Carson C, Rajfer J, Eardley I, et al. The efficacy and safety of tadalafil: an update. BJU Int 2004;93:1276-81
11. Fonseca V, Seftel A, Denne J, et al. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004;47:1914-23